Quest Diagnostics (NYSE:DGX) Stock Rating Reaffirmed by Truist Financial

Quest Diagnostics (NYSE:DGXGet Free Report)‘s stock had its “hold” rating reaffirmed by stock analysts at Truist Financial in a report issued on Wednesday, Benzinga reports. They presently have a $145.00 price objective on the medical research company’s stock. Truist Financial’s price objective indicates a potential upside of 12.55% from the company’s previous close.

DGX has been the subject of a number of other reports. Barclays started coverage on shares of Quest Diagnostics in a research report on Wednesday, January 3rd. They issued an “equal weight” rating and a $145.00 price objective for the company. Jefferies Financial Group upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and raised their price objective for the company from $140.00 to $155.00 in a research report on Wednesday, February 7th. TheStreet lowered shares of Quest Diagnostics from a “b-” rating to a “c” rating in a research report on Monday, February 5th. Leerink Partnrs restated a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, February 26th. Finally, SVB Leerink began coverage on shares of Quest Diagnostics in a research report on Monday, February 26th. They set a “market perform” rating and a $135.00 target price for the company. Ten research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $144.18.

Get Our Latest Stock Analysis on DGX

Quest Diagnostics Stock Performance

NYSE DGX opened at $128.83 on Wednesday. Quest Diagnostics has a 52-week low of $119.59 and a 52-week high of $148.62. The company has a 50-day simple moving average of $128.05 and a 200 day simple moving average of $130.07. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.20 and a current ratio of 1.31. The company has a market capitalization of $14.26 billion, a PE ratio of 17.20, a price-to-earnings-growth ratio of 2.79 and a beta of 0.90.

Quest Diagnostics (NYSE:DGXGet Free Report) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.04. The firm had revenue of $2.29 billion during the quarter, compared to the consensus estimate of $2.25 billion. Quest Diagnostics had a net margin of 9.23% and a return on equity of 15.79%. The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the company earned $1.98 earnings per share. On average, research analysts predict that Quest Diagnostics will post 8.75 EPS for the current year.

Insider Buying and Selling

In related news, SVP Michael E. Prevoznik sold 5,611 shares of Quest Diagnostics stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total value of $706,312.68. Following the transaction, the senior vice president now directly owns 38,478 shares of the company’s stock, valued at $4,843,610.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 5,611 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total transaction of $706,312.68. Following the transaction, the senior vice president now directly owns 38,478 shares of the company’s stock, valued at approximately $4,843,610.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael E. Prevoznik sold 661 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total transaction of $83,378.54. Following the transaction, the senior vice president now directly owns 40,206 shares in the company, valued at $5,071,584.84. The disclosure for this sale can be found here. Insiders have sold a total of 15,150 shares of company stock valued at $1,913,202 over the last three months. 1.70% of the stock is owned by company insiders.

Institutional Trading of Quest Diagnostics

A number of hedge funds have recently modified their holdings of DGX. Pacifica Partners Inc. bought a new stake in shares of Quest Diagnostics during the 3rd quarter valued at $25,000. NBC Securities Inc. bought a new position in Quest Diagnostics in the 3rd quarter worth about $25,000. Altshuler Shaham Ltd bought a new position in Quest Diagnostics in the 4th quarter worth about $26,000. VisionPoint Advisory Group LLC boosted its stake in Quest Diagnostics by 100.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after purchasing an additional 109 shares in the last quarter. Finally, Chilton Capital Management LLC bought a new position in Quest Diagnostics in the 1st quarter worth about $28,000. Institutional investors own 87.76% of the company’s stock.

About Quest Diagnostics

(Get Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.